Literature DB >> 11587479

Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles.

M Berton1, P Turelli, D Trono, C A Stein, E Allémann, R Gurny.   

Abstract

PURPOSE: To investigate the potential use of polymeric nanoparticles for the delivery of antisense oligonucleotides in HIV-1-infected cell cultures.
METHODS: Phosphorothioate oligonucleotides were encapsulated into poly (D,L-lactic acid) nanoparticles. Two models of infected cells were used to test the ability of nanoparticles to deliver them. HeLa P4-2 CD4+ cells, stably transfected with the beta-galactosidase reporter gene, were first used to evaluate the activity of the oligonucleotides on a single-round infection cycle. The acutely infected lymphoid CEM cells were then used to evaluate the inhibition of the viral production of HIV-1 by the oligonucleotides.
RESULTS: The addition to infected CEM cells of nanoparticles containing gag antisense oligonucleotides in the nanomolar range led to strong inhibition of the viral production in a concentration-dependent manner. Similar results were previously observed in HeLa P4-2 CD4+ cells. Nanoparticle-entrapped random-order gag oligonucleotides had similar effects on reverse transcription. However, the reverse transcriptase activity of infected cells treated with nanomolar concentrations of free antisense and random oligonucleotides was not affected.
CONCLUSIONS: These results suggest that poly (D,L-lactic acid) nanoparticles may have great potential as an efficient delivery system for oligonucleotides in HIV natural target cells, i.e., lymphocytic cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587479     DOI: 10.1023/a:1010962507273

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

Review 1.  Novel mechanisms for antisense-mediated regulation of gene expression.

Authors:  B F Baker; B P Monia
Journal:  Biochim Biophys Acta       Date:  1999-12-10

Review 2.  Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides.

Authors:  A M Krieg
Journal:  Biochim Biophys Acta       Date:  1999-12-10

3.  The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.

Authors:  K Yamaguchi; B Papp; D Zhang; A N Ali; S Agrawal; R A Byrn
Journal:  AIDS Res Hum Retroviruses       Date:  1997-05-01       Impact factor: 2.205

4.  Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture.

Authors:  C F Bennett; D Mirejovsky; R M Crooke; Y J Tsai; J Felgner; C N Sridhar; C J Wheeler; P L Felgner
Journal:  J Drug Target       Date:  1998       Impact factor: 5.121

5.  A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA.

Authors:  J G Lewis; K Y Lin; A Kothavale; W M Flanagan; M D Matteucci; R B DePrince; R A Mook; R W Hendren; R W Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

Review 6.  Cellular delivery of antisense oligonucleotides.

Authors:  I Lebedeva; L Benimetskaya; C A Stein; M Vilenchik
Journal:  Eur J Pharm Biopharm       Date:  2000-07       Impact factor: 5.571

7.  Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking.

Authors:  A Mangasarian; V Piguet; J K Wang; Y L Chen; D Trono
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Inhibition of human immunodeficiency virus type 1 activity in vitro by oligonucleotides composed entirely of guanosine and thymidine.

Authors:  J Ojwang; A Elbaggari; H B Marshall; K Jayaraman; M S McGrath; R F Rando
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-06

9.  Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans.

Authors:  G J Nabel; E G Nabel; Z Y Yang; B A Fox; G E Plautz; X Gao; L Huang; S Shu; D Gordon; A E Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

10.  Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms.

Authors:  O Zelphati; J L Imbach; N Signoret; G Zon; B Rayner; L Leserman
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971

View more
  6 in total

Review 1.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

Review 2.  Nanoparticles in modern medicine: state of the art and future challenges.

Authors:  Shashi K Murthy
Journal:  Int J Nanomedicine       Date:  2007

Review 3.  Nanotechnology: intelligent design to treat complex disease.

Authors:  Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.580

4.  Development of a magnetic electrochemical bar code array for point mutation detection in the H5N1 neuraminidase gene.

Authors:  Ludmila Krejcova; David Hynek; Pavel Kopel; Miguel Angel Merlos Rodrigo; Vojtech Adam; Jaromir Hubalek; Petr Babula; Libuse Trnkova; Rene Kizek
Journal:  Viruses       Date:  2013-07-15       Impact factor: 5.048

5.  Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting.

Authors:  Gyati Shilakari Asthana; Abhay Asthana; Dharm Veer Kohli; Suresh Prasad Vyas
Journal:  Biomed Res Int       Date:  2014-06-26       Impact factor: 3.411

6.  Therapeutic implications of nano-encapsulated rifabutin, azithromycin & ethambutol against experimental Mycobacterium avium infection in mice.

Authors:  Tapinder Kaur Grewal; Shahnawaz Majeed; Sadhna Sharma
Journal:  Indian J Med Res       Date:  2018-06       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.